BOULDER, Colo., Aug. 3, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq:  ARRY) will report financial results for the fourth quarter and full year of fiscal 2017 and hold a conference call to discuss those results on Wednesday, August 9, 2017.  Ron Squarer, Chief Executive Officer, will lead the call.

Webcast, including Replay and Conference Call Slides:
http://edge.media-server.com/m/p/af6yqtav

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.  Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).

View original content with multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-fourth-quarter-and-full-year-of-fiscal-2017-on-august-9-2017-300499225.html

SOURCE Array BioPharma